Document:

EX-10.2

 Exhibit 10.2 
  

 
 May 28, 2021 
 Jan Stern
Reed 
 2355 West Course Drive 
 Riverwoods, Illinois 60015 

Re: Appointment to Board of Directors 
 Dear
Ms. Reed: 
 I am pleased to confirm our offer regarding your appointment as a member of the Board of Directors of AVITA Medical Inc., a
Delaware corporation (the “Company”), which will commence with effect on July 1, 2021 (the “Effective Date”), on the following terms: 

 

	1.	 Position. 

Your position as a Director of the Company will require formal acceptance of this appointment, by executing this letter agreement as of a date
no later than July 1, 2021. Your term as a Director will commence on the Effective Date and you will be subject to annual re-election by the shareholders at the Company’s annual shareholder meeting
which takes place on or around October/November of each year. 
  

	2.	 Duties. 

(a) As a non-executive director your duties involve commitment of your time to board meetings. We
currently have four scheduled meetings per year which is subject to re-examination next year in which the frequency of the meetings may increase, plus additional board meetings, including strategy meetings.
Additionally, there are committee meetings to which you may be appointed and we currently have four scheduled meetings per year per committee which is subject to re-examination next year in which the frequency
of the meetings may increase. Whilst there is a clear need for in-person meetings, during unforeseen events, such as the current pandemic, your attendance may be requested via teleconferencing. 

(b) The Company understands and agrees that during your term as a Director you may serve in other capacities for the Company, including as an
executive, consultant or advisor, and that you may also serve in like capacities for other companies not affiliated with the Company that are not Company competitors, subject to your obligations contained in this letter agreement. Any potential new
appointments should be discussed with the Board Chair prior to acceptance, to allow consideration of matters including conflict of interest, and the time you can devote to your position as a non-executive
director of AVITA. 
 AVITA Medical 

28159 Avenue Stanford, Suite 220 Valencia, CA 91355 

P +1(661) 367-9170 | f +1 (661) 367-9180 | avitamedical.com 

 

 
  

	3.	 Compensation. 

In consideration for your services to the Company as a non-executive Director, your current base
compensation, which is subject to shareholder approval at the annual shareholder meeting, is US $70,000 annually with additional paid membership of one or more committees that will be discussed with you in due course. Cash remuneration for board
directors is reviewed periodically with reference to peer company compensation, and is subject to shareholder approval. An equity component of your compensation is expected to be added, subject to shareholder approval at the annual shareholder
meeting scheduled on or around October/November, 2021. 
  

	4.	 Expenses. 

As a non-executive Director you are entitled to reimbursement for reasonable company- related
expenditures incurred by you, including your travel to and from Board meetings, after receipt by the Company from you of an itemized expense report, together with receipts or other reasonable proof of such expenses. Travel is usually coordinated
through the office of the CEO. 
  

	5.	 Representations and Warranties. 

(a) You represent and warrant that (i) your performance of your obligations under this letter agreement will not infringe any intellectual
property, publicity or privacy rights of any third party, (ii) neither your advisory relationship with the Company, nor the performance of your obligations hereunder, will conflict with or result in a breach of any third-party agreement by
which you are currently bound, and (iii) your performance of your obligations under this letter agreement will not contain any defamatory or libelous material or material that discloses private or personal matters concerning any party, without
that party’s consent. 
 (b) You further understand that your role as a Director will be that of an independent contractor and that you
will not be an agent, employee or representative of the Company. You further understand that you will have no authority to enter into contracts or create obligations on the Company’s behalf. You acknowledge that you will not be eligible for any
employee benefits and that the Company will not make any tax withholdings on your behalf. You agree that you are obligated to report as income all consideration that you receive in connection with this letter agreement, and you agree to pay any
applicable self-employment and other taxes thereon, if any. You further agree to indemnify the Company and hold it harmless to the extent of any obligation imposed on the Company (i) to pay withholding taxes or similar items or
(ii) resulting from your being determined not to be an independent contractor. All compensation paid to you shall be reported by the Company to the Internal Revenue Service and any applicable state tax authorities on a Form 1099 or other
applicable form. 
  

	6.	 Confidential Information. 

You agree that you will (i) hold in strictest confidence the Company’s proprietary information and trade secrets and all other
information made known to you in connection with your relationship with the Company as a Director that has or could have commercial value or other utility in the Company’s business or prospective business (collectively, the
“Confidential Information”), and (ii) not use the Confidential Information except in connection with your relationship with the Company as a Director. 

  
 AVITA Medical 

28159 Avenue Stanford, Suite 220 Valencia, CA 91355 

P +1(661) 367-9170 | f +1 (661) 367-9180 | avitamedical.com 

 

 
  

 The Confidential Information will not include information that you can establish is or was
(i) received by you without an obligation of confidentiality from an unrelated third party that is not under an obligation of confidentiality to the Company and that has a legal right to disclose it, (ii) generally known or available in
the industry or to the general public either (A) prior to the Company’s disclosure of such information to you or (B) after the Company’s disclosure of such information to you through no action or inaction by you, or
(iii) required to be disclosed by applicable law, by order of court or the rules, regulations or order of any governmental agency. 

You agree that you will not improperly use or disclose any proprietary information or trade secrets received by you from any third party in
connection with your relationship with the Company as a Director. You recognize that the Company has received and in the future will receive confidential and proprietary information from third parties and that the Company will have a duty to
maintain the confidentiality of such information and to use it only for certain limited purposes. You agree to hold all such confidential and proprietary information in the strictest confidence, and you further agree that you will neither disclose
it to any person, firm or corporation nor use it in a manner that is inconsistent with the Company’s obligations to such third parties. 

To the extent that your service to the Company results directly in the creation of any new Intellectual Property (as defined below), you agree
that, as between you and the Company, the Company shall own the rights to such new Intellectual Property if such Intellectual Property (i) is developed using the equipment, facilities, supplies or Confidential Information of the Company, or
(ii) results from or is suggested by work performed by you on behalf of the Company, but only if you are explicitly engaged in performing direct work for the Company. For the purposes of this section, “Intellectual
Property” means any original works of authorship, inventions, concepts, improvements or trade secrets, whether or not patentable or registrable under copyright or similar laws. At the Company’s expense, you agree to execute all
documents and take all actions necessary or reasonably requested by the Company to document, perfect or assign the Company’s rights to Intellectual Property. Further, if you fail or refuse to execute any such instruments, you hereby appoint the
Company as your attorney-in-fact (this appointment to be irrevocable and a power coupled with an interest) to act on your behalf and to execute such documents. 

Upon the Company’s request at and after such time as your term as a Director terminates, you agree to return, and will not keep in your
possession, recreate or deliver to any third party, any and all documents and/or electronic files containing Confidential Information. 
  

	7.	 Indemnification. 

The Company will agree to defend and indemnify you and hold you harmless against liability that you incur within the scope of your service as a
Director of the Company to the fullest extent provided under Delaware law and pursuant to and in accordance with all of the terms and conditions contained in the Indemnification Agreement on the Company’s standard form to be separately provided
to you, which is to be executed and delivered by you and the Company upon execution and delivery of this letter agreement. 
  

	8.	 Publicity. 

You and the Company agree to cooperate with each other to create any and all appropriate public or promotional announcements or press releases
concerning our relationship. 

  
 AVITA Medical 

28159 Avenue Stanford, Suite 220 Valencia, CA 91355 

P +1(661) 367-9170 | f +1 (661) 367-9180 | avitamedical.com 

 

 
  

	9.	 Term and Termination. 

This letter agreement will commence on the Effective Date and will continue until such time as your term as a Director terminates. Upon such
termination all our rights and duties towards each other shall cease, except that this Section 9 and Sections 5, 6, 7 and 10 shall survive termination of this letter agreement. 

 

	10.	 Other Provisions. 

Entire Agreement; Governing Law. This letter agreement constitutes the entire agreement between you and the Company and supersedes and
replaces any prior or contemporaneous agreements, representations or understandings, whether written, oral or implied, between you and the Company. This letter agreement will be interpreted, construed and enforced in all respects in accordance with
the laws of the State of Delaware, without regard to its conflict of laws rules. 
 Severability; Counterparts. If any provision of
this letter agreement is declared by any court of competent jurisdiction to be illegal, void or unenforceable, all other provisions will not be affected and will remain in full force and effect. This letter agreement may be executed in counterparts,
each of which is an original and which together constitute a single agreement. 
 Equitable Relief. You understand that monetary
damages will not adequately compensate the Company for a breach of your obligations. Accordingly, you agree that the Company may specifically enforce this letter agreement and that the Company will be entitled to seek a temporary or permanent
injunction or restraining order to prevent any breach or threatened breach of your obligations under this letter agreement. You thus hereby waive any claim or defense that there is an adequate remedy at law for such breach or threatened breach and
further agree that no bond or other security will be required in obtaining such equitable relief. 
 Assignment. You may not assign
your rights or obligations under this letter agreement without the Company’s prior written consent. You understand that the Company may assign this letter agreement without your consent to any entity (i) resulting from any merger,
consolidation or other reorganization involving the Company, including, without limitation, a merger or other reorganization for the purpose of changing the Company’s domicile, or (ii) to which the Company transfers all or substantially
all of its assets. 
 [Signatures on following page] 

  
 AVITA Medical 

28159 Avenue Stanford, Suite 220 Valencia, CA 91355 

P +1(661) 367-9170 | f +1 (661) 367-9180 | avitamedical.com 

 

 
  

 Please acknowledge your agreement to these terms by signing and dating a copy of this letter agreement where
indicated and returning it to the Company at our address listed below. 
  

			
	Sincerely,
	
	AVITA Medical, Inc.
		
	By:	 	 /s/ Dr. Michael S. Perry

	Name:	 	Dr. Michael S. Perry
	Title:	 	Chief Executive Officer
	
	Company Address:
	
	28159 Avenue Stanford, Suite 220
	Valencia, California 91355

  

			
	AGREED AND ACKNOWLEDGED:
		
	 /s/ Jan Stern Reed
	  	Date: May 31, 2021
	(Signature)	  	
		
	 Jan Stern Reed
	  	
	(Print Name)	  	
		
	Address:	  	
	2355 West Course Drive	  	
	Riverwoods, IL 60015	  	
	  
	  	

  
 AVITA Medical 

28159 Avenue Stanford, Suite 220 Valencia, CA 91355 

P +1(661) 367-9170 | f +1 (661) 367-9180 | avitamedical.comEX-4.2

 Exhibit 4.2 
  

 
 . ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK COMMON STOCK PO PAR VALUE $0.0001 MR ADD ADD
ADD ADD 4 3 2 1 A BOX DESIGNATION SAMPLE Certificate Shares 505006, Number 000000 (IF 000000 ANY) ZQ00000000 000000 Louisville, MONTE ROSA THERAPEUTICS, INC. 000000 KY 000000 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE Mr. Alexander David
Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample SEE REVERSE FOR CERTAIN DEFINITIONS 40233 Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr.
Alexander David Sample Mr. Alexander David - THIS CERTIFIES THAT Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. MR. Alexander David SAMPLE Sample Mr.
Alexander David &Sample MRS. Mr. Alexander SAMPLE David Sample Mr. Alexander & David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr Alexander David Sample Mr. Alexander David Sample CUSIP 61225M 10
2 5006 Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample
Mr. Alexander David Sample Mr. Alexander MR. David Sample SAMPLE Mr. Alexander David Sample &Mr. Alexander MRS. David Sample SAMPLE Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David
Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander
David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Sample Mr. Sample is the owner of 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000
Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 0
THIS CERTIFICATE IS TRANSFERABLE IN 00000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 00 ZERO^HUNDRED THOUSAND 0000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000
Shares 000000 Shares 000000 Shares 000 CITIES DESIGNATED BY THE TRANSFER 000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 0000 AGENT, AVAILABLE ONLINE AT 00 Shares 000000 Shares 000000
Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 00000 0 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 ZERO HUNDRED AND ZERO www.computershare.com Shares
000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000
Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 S FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF Monte Rosa Therapeutics, Inc. (hereinafter called the
“Company”), transferable on the books of the Total DTC Company in person or by duly authorized attorney, upon surrender of this Certificate properly endorsed. This Holder Certificate and the shares represented hereby, are issued and shall
be held subject to all of the provisions of the Number Certificateof Insurance ID Certificate of Incorporation, as amended, and the By-Laws, as amended, of the Company (copies of which are on Value file with
the Company and with the Transfer Agent), to all of which each holder, by acceptance hereof, assents. Transaction Shares CUSIP/IDENTIFIER This Certificate is not valid unless countersigned and registered by the Transfer Agent and Registrar. Numbers
1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 Witness the facsimile seal of the Company and the facsimile signatures of its duly authorized officers. DATED DD-MMM-YYYY HER T AP COUNTERSIGNED AND REGISTERED: FACSIMILE SIGNATURE TO COME A E S POR R A U COMPUTERSHARE TRUST COMPANY, N.A. Num/No
12345678901234512345678    O CO TE T R I Denom. President C TRANSFERâ€^AGENT ANDâ€^REGISTRAR, T E S , 666 555 444 333 222 111 N N I O . C XXXXXX M 11/21/2019 Total. DEL RE FACSIMILE SIGNATURE TO COME AWA 7
00.1,000,000 XX 123456 XXXXXXXXXX X By Secretary AUTHORIZEDâ€^SIGNATURE     

 

 
 MONTE ROSA THERAPEUTICS, INC THE COMPANY WILL FURNISH WITHOUT CHARGE TO EACH SHAREHOLDER WHO SO REQUESTS, A SUMMARY OF THE POWERS,
DESIGNATIONS, PREFERENCES AND RELATIVE, PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OF THE COMPANY AND THE QUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH PREFERENCES AND RIGHTS, AND THE VARIATIONS IN RIGHTS,
PREFERENCES AND LIMITATIONS DETERMINED FOR EACH SERIES, WHICH ARE FIXED BY THE CERTIFICATE OF INCORPORATION OF THE COMPANY, AS AMENDED, AND THE RESOLUTIONS OF THE BOARD OF DIRECTORS OF THE COMPANY, AND THE AUTHORITY OF THE BOARD OF DIRECTORS TO
DETERMINE VARIATIONS FOR FUTURE SERIES SUCH REQUEST MAY BE MADE TO THE OFFICE OF THE SECRETARY OF THE COMPANY OR TO THE TRANSFER AGENT THE BOARD OF DIRECTORS MAY REQUIRE THE OWNER OF A LOST OR DESTROYED STOCK CERTIFICATE, OR HIS LEGAL
REPRESENTATIVES, TO GIVE THE COMPANY A BOND TO INDEMNIFY IT AND ITS TRANSFER AGENTS AND REGISTRARS AGAINST ANY CLAIM THAT MAY BE MADE AGAINST THEM ON ACCOUNT OF THE ALLEGED LOSS OR DESTRUCTION OF ANY SUCH CERTIFICATE The following abbreviations,
when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: TEN COM—as tenants in common UNIF GIFT MIN ACT - Custodian (Cust) (Minor) TEN
ENT —as tenants by the entireties under Uniform Gifts to Minors Act (State) JT TEN —as joint tenants with right of survivorship UNIF^TRF MIN ACT — Custodian (until age ) and not as tenants in common (Cust) under Uniform Transfers to
Minors Act (Minor) (State) Additional abbreviations may also be used though not in the above list PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE For value received, hereby sell, assign and transfer unto (PLEASE PRINT OR
TYPEWRITE NAME AND ADDRESS, INCLUDING POSTAL ZIP CODE, OF ASSIGNEE) Shares of the common stock represented by the within Certificate, and do hereby irrevocably constitute and appoint Attorney to transfer the said stock on the books of the
within-named Company with full power of substitution in the premises Dated: 20 Signature(s) Guaranteed: Medallion Guarantee Stamp THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (Banks, Stockbrokers, Savings and Loan
Associations and Credit Unions) WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S E C RULE 17Ad-15 Signature: Signature: Notice: The signature to this assignment must
correspond with the name as written upon the face of the certificate, in every particular, without alteration or enlargement, or any change whatever The IRS requires that the named transfer agent (“we”) report the cost basis of certain
shares or units acquired after January 1, 2011 If your shares or units are covered by the legislation, and you requested to sell or transfer the shares or units using a specific cost basis calculation method, then we have processed as you
requested If you did not specify a cost basis calculation method, then we have defaulted to the first in, first out (FIFO) method Please consult your tax advisor if you need additional information about cost basis If you do not keep in contact with
the issuer or do not have any activity in your account for the time period specified by state law, your property may become subject to state unclaimed property laws and transferred to the appropriate state

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]